QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of ezogabine, abarelix and ezogabine. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for ezogabine, when combined with abarelix (100%) and ezogabine (100%). We do not expect any change in exposure for abarelix, when combined with ezogabine (100%) and ezogabine (100%). We do not expect any change in exposure for ezogabine, when combined with ezogabine (100%) and abarelix (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of ezogabine is unknown. Protein binding [ Pb ] is not known. The metabolism does not take place via the common cytochromes and the active transport takes place partly via UGT1A1 and UGT1A9.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
Ezogabine has a mean oral bioavailability [ F ] of 60%, which is why the maximum plasma levels [Cmax] tend to change with an interaction. The terminal half-life [ t12 ] is 8 hours and constant plasma levels [ Css ] are reached after approximately 32 hours. The protein binding [ Pb ] is rather weak at 70%. The metabolism via cytochromes is currently still being worked on.
|Serotonergic Effects a||0||Ø||Ø||Ø|
Rating: According to our knowledge, neither ezogabine, abarelix nor ezogabine increase serotonergic activity.
|Kiesel & Durán b||0||Ø||Ø||Ø|
Rating: According to our knowledge, neither ezogabine, abarelix nor ezogabine increase anticholinergic activity.
QT time prolongation
Rating: In combination, ezogabine, abarelix and ezogabine can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||ezo||aba||ezo|
|Coordination problem||13.5 %||7.0||n.a.||7.0|
|Disturbance of attention||11.6 %||6.0||n.a.||6.0|
|Memory impairment||11.6 %||6.0||n.a.||6.0|
Blurred vision (9.8%): ezogabine, ezogabine
Ataxia (7.8%): ezogabine, ezogabine
Dysarthria (7.8%): ezogabine, ezogabine
Impairment of balance (7.8%): ezogabine, ezogabine
Hallucinations (4%): ezogabine, ezogabine
Psychosis (2%): ezogabine, ezogabine
Suicidal: ezogabine, ezogabine
Urinary retention (2.9%): ezogabine, ezogabine
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
Abstract: Retigabine, a first-in-class selective M-current potassium channel opener, is a novel antiepileptic compound currently in clinical development. The purpose of this randomized placebo-controlled study was to assess retigabine oral safety and pharmacokinetics in healthy male volunteers (N = 45). Subjects received one dose on day 1 and doses every 12 hours for the next 14 days. Fixed doses were given to the first four groups (200, 400, 500, and 600 mg per day). Titrated doses were given to group 5 in 100 mg increases every 4 days, achieving 700 mg per day on day 15. Serial blood samples were collected on days 1 and 15. Pharmacokinetic parameters were compared between days and among dose groups. After administration of a single dose, retigabine was rapidly absorbed, with maximum concentrations of 387 ng/ml (normalized to a 100 mg dose) occurring within 1.5 hours. Retigabine was eliminated with a mean terminal half-life of 8.0 hours and an apparent oral clearance of 0.70 L/h/kg in white subjects. In black subjects, retigabine clearance and volume of distribution were 25% and 30% lower, respectively, after normalizing by body weight, leading to higher exposure in this population. Retigabine's pharmocokinetics was linearly dose proportional. Steady-state pharmacokinetics was in agreement with single-dose pharmacokinetics, and the accumulation ratio was about 1.5. Retigabine and AWD21-360 trough evening concentrations were significantly lower (about 30% to 35%) than morning values. The titration regimen allowed for higher doses to be tolerated compared to the fixed-dose regimen. In conclusion, the pharmacokinetics of retigabine is linearly dose proportional for daily doses of 100 to 700 mg and is not modified on multiple administrations.